AGP Picks
View all

Varivax market set for growth as immunization programs expand

2 hours ago
Varivax market set for growth as immunization programs expand
By AI, Created 15:15 UTC, Nov 19, 2026, AGP -

The global Varivax (varicella) vaccine market is expected to grow through 2035 as childhood immunization schedules, adult vaccination efforts and broader access to vaccines expand. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Varivax protects against chickenpox, a preventable infection that can still cause complications and public health costs. - Demand for the vaccine is rising as governments expand immunization programs and broaden access to preventive care. - The market outlook also signals where vaccine access, healthcare spending and disease surveillance are likely to shape demand through 2035.

What happened: - The Business Research Company published its Varivax (varicella) Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Varivax market is poised for substantial growth. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Varivax is a live attenuated vaccine designed to protect against chickenpox caused by the varicella-zoster virus. - The vaccine works by stimulating the immune system to build defenses that can prevent infection or reduce severity after exposure. - Historical market growth has been linked to frequent chickenpox outbreaks, pediatric vaccination schedules, mandatory school immunizations, public health awareness and regulatory approvals. - Future growth is expected to come from greater use of the MMRV vaccine, broader adult immunization programs, stronger disease monitoring, higher healthcare investment and improved vaccine access. - Key trends include wider routine childhood immunization, broader acceptance of combination vaccines, government vaccination mandates, better cold chain logistics and more awareness of preventable viral infections. - The report says immunization programs help distribute Varivax more broadly, support herd immunity, reduce chickenpox cases and protect at-risk populations. - In January 2024, the UK National Health Service launched a vaccine strategy centered on community-based services for underserved groups, using multidisciplinary teams to improve access and outreach. - Rising birth rates are another market driver because Varivax helps reduce the risk of chickenpox-related pregnancy complications, including congenital varicella syndrome. - Data from the Australian Bureau of Statistics in October 2024 showed Aboriginal and Torres Strait Islander births in 2023 were up by 349 from 2022. - Healthcare spending is also supporting vaccine access and market growth. - The UK Office for National Statistics said in May 2023 that UK healthcare spending rose 5.6% from 2022 to 2023, reaching about $317.63 billion (£292 billion). - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full report through links provided by The Business Research Company: Free sample report and Full market report.

Between the lines: - The report frames the market as a mix of public health policy, demographics and healthcare infrastructure rather than a simple product sales story. - Wider immunization coverage and rising healthcare spending can expand access, but the market still depends on government adoption and delivery systems that reach underserved populations. - North America's lead suggests established vaccination infrastructure, while Asia-Pacific's growth points to room for catch-up demand and broader program rollout.

What's next: - The market is expected to keep growing as combination vaccines gain acceptance and adult immunization expands. - Improved monitoring systems and vaccine logistics should support wider distribution and uptake. - The report's forecast runs through 2035, with added tools such as dashboards and scoring models aimed at tracking future opportunities.

The bottom line: - Varivax demand is being pushed by public health policy, rising births, higher healthcare spending and broader vaccine access, with the strongest future growth expected in Asia-Pacific.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Business Times Australia

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Business Times Australia

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.